Brind.

AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.

2 reports, 0 independent Updated Jun 29

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.

Who's involved

What this event is mainly about

AbbVie Donald Trump HUMIRA

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
HUMIRA
Czech company
- Lost patent protection for Humira in the US on August 20, 2025.Thu 06:13

Related events

A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.Jun 7

Coverage

Newest first; wire copies grouped

Jun 29Unknown outlet
Jun 21Unknown outlet